140064
137211


Canopy Growth growing

Canopy Growth Corp. has signed a deal to buy a German company that specializes in cannabinoid-based medical therapies used by European physicians for roughly $342.9 million.

Under the deal, the Ontario-based company has acquired C3 Cannabinoid Compound Co.

C3's main medicinal offering is dronabinol, a compound with standardized concentrations of THC (tetrahydrocannabinol), the main psychoactive compound in cannabis.

Dronabinol is available in Austria, Denmark and Germany.

C3 has two manufacturing facilities specializing, respectively, in natural extraction and synthetic cannabinoid production.

The company's senior management team is expected to continue with the business.



More Business News

138100
137595
137176
Data from CryptoCompare
Recent Trending
135522
Soft 103.9
141396
Castanet Proud Member of RTNDA Canada
Press Room
139255